AzTrials
AzTrials

Bariatric Surgery CandidateNCT05146232

Effect of Opioid Free Versus Opioid-Based Anesthesia on Cerebral Oximetry In Gastric Sleeve Operation

A study testing induction of anesthesia, maintainance of anesthesia and monitoring in people with Bariatric Surgery Candidate, run by Tanta University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Obesity and pneumoperitoneum in the reverse-Trendelenburg position during laparoscopic sleeve gastrectomy (LSG) are reported to negatively affect cerebral oxygenation. Anesthetic agents can have variable effects on the regional cerebral tissue oxygen saturation (rSO2) measured with near-infrared spectroscopy. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Bariatric Surgery Candidate
What is being tested?
induction of anesthesia, maintainance of anesthesia and monitoring
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
No sites listed yet
Study dates
5 Feb 2022to 30 Mar 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • ASAphysical status class II-III
  • Patients undergoing laparoscopic sleeve

Who cannot join

  • neurolgical diseases
  • cardiovascular diseases

About this study

Obesity and pneumoperitoneum in the reverse-Trendelenburg position during laparoscopic sleeve gastrectomy (LSG) are reported to negatively affect cerebral oxygenation. Anesthetic agents can have variable effects on the regional cerebral tissue oxygen saturation (rSO2) measured with near-infrared spectroscopy. This study investigated the potential impact of opioid free versus opioid based anesthesia on rSO2 in LSG cases. 80 American Society of Anesthesiologists (ASA) II-III patients, 18-65 years of age, with a body mass index of >35 kg/m2 , undergoing LSG were randomized to two groups: opioid free and opioid based groups for anesthesia maintenance. The rSO2 values were recorded preoperatively, 1 min after anesthesia induction, and every 5 min during surgery. Arterial blood gases (ABG) were measured in the fifth minute postinduction (t1), 30th minute postinsuflation (t2), and postextubation (t3), and correlation with rSO2 .

Read the detailed description

All study participants wiere provided a written informed consent before enrollment. 80 patients in the American Society of Anesthesiologists (ASA) physical status class II-III, 18-65 years of age, with a BMI of >35 kg/m2 who were planning to undergo an elective LSG were enrolled in the study. Patients with preexisting cerebrovascular diseases, overt neurological signs, alcohol or psychoactive drug addiction, uncontrolled diabetes or hypertension, advanced organ failure, preoperative peripheral oxygen saturation (SpO2) <96%, or a hemoglobin˂9g/dL were excluded.

Randomization for the investigation, the patients were randomly assigned using opaque sealed envelopes to two groups; Group (I) (n = 40): The Opioid based anesthesia: Pre-induction of general anesthesia a bolus of 2ug/kg/ IV Fentanyl (sunny pharmaceutical Egypt Company under License of Hameln pharmaceutical Germany) was administered then infusion of 1 ug/kg/h was given intraoperatively to maintain the change in hemodynamics within 20 % of the baseline , and Group (II) (n = 40): Opioid free anesthesia: Pre-induction of general anesthesia 1000 mg paracetamol (Pharco B international pharmaceutical-Egypt) and dexamethasone 0.1 mg/kg. Lidocaine 1 mg/kg (Alexandria co. for pharmaceutical and chemical industries-Egypt), ketamine 0.5 mg/kg were given I V bolus dose. Then continuous infusion with lidocaine 2 mg/kg/hr and magnesium sulfate (Manufactured by E.I.P.I.CO-. Egypt).1.5 g/hr was started. Local infiltration of skin incision with 0.25% bupivacaine at the end of the operation (Sunny pharmaceutical -Egypt) (n = 30). Randomization was performed according to a computer-generated randomization code, and a statement showing the patients' group was placed in a sealed, numbered envelope according to the results. Each patient drew an envelope and was enrolled in the study depending on the group written in the envelope. Randomization was performed by a physician who was not involved in the monitoring of the patients. The anesthesiologist caring for the patient was aware of the group assignments. The patients were blinded to the group assignments.

Anesthesia protocol all patients was administered 300 mg of oral ranitidine the night before the surgery and 10 mg IV metoclopramide in combination with 150 mg ranitidine 1 h before arrival to the operating room. Upon the arrival to the operating room, an electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients. Afterward, preoxygenation was performed with 4 L/min oxygen (80%) for 3 min by using facemasks, and anesthesia was induced with an IV propofol injection (1.5-2.5 mg/kg of ideal body weight) and an IV bolus administration of remifentanil (1 lg/kg of lean body weight [LBW]) for 30-60 s, and then switched to infusion at 0.25 lg/kg of LBW/min. After the eyelid reflex disappeared, a neuromuscular blockade was performed using rocuronium (1.2 mg/kg of LBW) and tracheal intubation was done. Volume-controlled mechanical ventilation was applied. Breathing gases (oxygen, carbon dioxide and sevoflurane), the tidal volume were set as 7-8 mL/kg of LBW, inspiratory:expiratory ratio as 1:2, positive end-expiratory pressure as 5-8 cmH2O, and the respiratory rate was determined to obtain an end-tidal carbon dioxide partial pressure (PETCO2) of 32-37 mmHg. These ventilator settings were not changed throughout the operation. Oxygen/air (fraction of inspired oxygen [FiO2] of 0.40), inspiratory fresh gas flow of 2 L/min), sevoflurane (1 minimum alveolar concentration [MAC]), and remifentanil IV infusion (0.1-0.25 lg/kg of LBW/min) were used in the for the maintenance of anesthesia. Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3- 0.7 mg/kg of LBW/h). IV normal saline or lactated Ringer's solution at 5-7 mL/kg of LBW was also used for perioperative fluid maintenance. Nasopharyngeal temperature was monitored throughout the surgery, and the patient temperature (36-37C) was ensured by using a forced-air warming system for the maintenance of intraoperative normothermia during the procedure. After anesthesia induction, a neutral head position of the patients was preserved to prevent alteration of cerebral venous drainage. Carbon dioxide insufflation was performed with an electronic laparoflator using a closed Veress needle technique, and intra-abdominal pressure was automatically kept at the desired level (14-16 mmHg) during the surgery. After the insufflation of carbon dioxide, the patients were positioned in a 30 reverse-Trendelenburg and at a 10 right lateral position. At the end of the surgery, the blockade was reversed by administering 4 mg/kg of adjusted body weight sugammadexwith a PTC of 1-2. All patients were extubated when fully awake. The patients were referred to the recovery unit and monitored for 50 min for complications. In cases where no complications was apparent, the recovery was evaluated using the modified Aldrete scoring system. Once the score was ≥9, the patients were taken to the unit. For postoperative nausea and vomiting, 4-5 mg dexamethasone was used (except for diabetic patients on insulin) 90 min before anesthesia induction and 4-8 mg IV ondansetron 20-30 min before the end of the operation. For postoperative pain management, 1 g IV acetaminophen was administered 20 min after induction and 30 mg IV ketorolac 20 min before onset. Then, 1 g IV acetaminophen was administered every 6 h + 50 mg IV dexketoprofen every 8 h for the first 48 h. In addition, morphine was administered using a patient-controlled analgesia delivery system (demand dose, 20 lg/kg of ideal body weight; lockout time, 6-10 min; 4 h limit, 80% of the total calculated dosage) for 48 h postoperatively.

Intraoperative measurements, physiological variables including heart rate (HR), MAP, SpO2, and PETCO2 were recorded preoperatively, 1 min after the induction, and every 5 min until the patient was referred to the recovery unit. The MAP and HR values were allowed to fluctuate up to 20% of the preoperative values of the patients. For this purpose, the infusion rate of remifentanil was accordingly increased and decreased. When hypotension (MAP ˂60 mmHg) or bradycardia (HR˂45beats/min) continued for longer than 3 min, they were treated with 5 mg ephedrine and 0.5 mg atropine, respectively. Patients who received ephedrine or atropine more than twice were excluded from the study.

Cerebral oxygen saturation. The rSO2 values of the patients were recorded preoperatively, 1 min after the induction, and every 5 min until the patient was referred to the recovery unit. Measurements in the last 30 s of preoxygenation, performed for 3 min with 4 L/min oxygen (80%) preinduction was accepted as preoperative values. To assess rSO2, cerebral oximetry sensors were placed at least 2 cm above the left and right eyebrows and 3 cm from the midline (to prevent the sagittal sinus from influencing the results) before the induction in accordance with the manufacturer's instructions. Before applying the sensor pads, the forehead of the patient was cleaned with acetone alcohol and bandaged to protect the sensors from ambient light and to keep them stable. Cerebral oxygen desaturation was defined as a >25% decrease in the rSO2 value compared with the preoperative value (decrease should be more than 20% if the preoperative value was˂50) and maintenance of this situation for≥15s. In this case, the following algorithm was used. First of all, normotension of the patient was ensured (administration of vasopressors such as ephedrine, and/or infusion of isotonic fluids) and the patient's neck were checked. Operating times. anesthesia, surgery, pneumoperitoneum, and recovery times were recorded. Recovery time was defined as the time from discontinuation of sevoflurane or propofol and remifentanil at the end of the surgery to the restoration of spontaneous breathing, opening of the eyes upon a verbal command, squeezing of the hand of the observer and extubation. Additionally, the complications (including nausea and vomiting) developed by the patients were also recorded.

Being tested
induction of anesthesia, maintainance of anesthesia, monitoring, First postoperative analgesia, Second postoperative analgesia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • induction of anesthesiaOther

    induction of anesthesia during gastric sleeve surgery

  • maintainance of anesthesiaOther

    maintainance of anesthesia during gastric sleeve surgery either opioid free or opioid based

  • monitoringOther

    electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients.

  • First postoperative analgesiaOther

    IV acetaminophen will be administered every 6 h

  • Second postoperative analgesiaOther

    50 mg IV dexketoprofen every 8 h for the first 48 h.

Study groups in NCT05146232
Study groupRoleWhat they receive
Opioid free groupActive comparatorAfter induction of aesthesia, anesthesia maintained by sevoflurane and continuous unfusion of lidocaine, ketamine, dexmeditomedine and Paracetamol.
Receives: Other: induction of anesthesia; Other: maintainance of anesthesia; Other: monitoring; Other: First postoperative analgesia; Other: Second postoperative analgesia
Opioid based groupActive comparatorAfter induction of aesthesia, anesthesia maintained by continuous remifentanyl infusion
Receives: Other: induction of anesthesia; Other: maintainance of anesthesia; Other: monitoring; Other: First postoperative analgesia; Other: Second postoperative analgesia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes of regional cerebral oxygen saturation percentage

    Measred noninvasively by electrodes of Masimo oximeter on all patient' forehead before induction of anesthesia

    Measured: Measured preoperatively, 1 minute after the induction, and every 5 minutes until the patient will be referred to the recovery unit.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Dec 2021
  2. Study start5 Feb 2022 (estimated)
  3. Primary completion30 Mar 2022 (estimated)
  4. Study completion30 Mar 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
The rSO2 values will be recorded preoperatively, 1 min after anesthesia induction, and every 5 min during surgery. Arterial blood gases (ABG) will be measured in the fifth minute postinduction (t1), 30th minute postinsufflation (t2), and postextubation (t3), and correlation with rSO2 will be examined.
Masking
Single blind
Who is masked
Participant
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05146232
Sponsor's protocol ID
34777/7/21
Status last verified
Dec 2021
First submitted
6 Nov 2021
Last updated
1 Feb 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing induction of anesthesia, maintainance of anesthesia and monitoring in people with Bariatric Surgery Candidate, run by Tanta University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes of regional cerebral oxygen saturation percentage (time frame: Measured preoperatively, 1 minute after the induction, and every 5 minutes until the patient will be referred to the recovery unit.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Feb 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in